We're wrapping up the final preparations for tomorrow's big webinar on landing the best deal for your biotech company, and I want to 
give readers one last opportunity to take FierceBiotech's short survey on deal-making plans. Over the last year we've seen pharma companies turning increasingly to new alliances as a low-cost, low-risk approach to drug development. And the trend has had a profound impact on the biotech industry. Let us know more about where you stand in the process here. It will only take about a minute. - John Carroll